MCID: OVR106
MIFTS: 43

Ovarian Clear Cell Carcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Clear Cell Carcinoma

MalaCards integrated aliases for Ovarian Clear Cell Carcinoma:

Name: Ovarian Clear Cell Carcinoma 12 15
Clear-Cell Ovarian Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050934

Summaries for Ovarian Clear Cell Carcinoma

Disease Ontology : 12 An ovarian carcinoma that has material basis in cells with clear cytoplasm and glycogen secreting hob nail cells.

MalaCards based summary : Ovarian Clear Cell Carcinoma, also known as clear-cell ovarian carcinoma, is related to adenofibroma and clear cell adenocarcinoma. An important gene associated with Ovarian Clear Cell Carcinoma is ARID1A (AT-Rich Interaction Domain 1A), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Paclitaxel and Topotecan have been mentioned in the context of this disorder. Affiliated tissues include ovary, kidney and lymph node, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 73 Clear cell ovarian carcinoma is one of several subtypes of ovarian carcinoma. Clear cell is a subtype of... more...

Related Diseases for Ovarian Clear Cell Carcinoma

Diseases in the Ovarian Clear Cell Carcinoma family:

Ovarian Small Cell Carcinoma

Diseases related to Ovarian Clear Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 277)
# Related Disease Score Top Affiliating Genes
1 adenofibroma 31.2 TP53 NAPSA KRT7 ARID1A
2 clear cell adenocarcinoma 31.1 TP53 PIK3CA NAPSA KRT7 HNF1B ARID1A
3 clear cell adenocarcinoma of the ovary 31.1 GPC3 CCNE1
4 clear cell adenofibroma 30.9 PPP2R1A PIK3CA NAPSA ARID1A
5 cystadenoma 30.8 PTEN KRT7 HIF1A
6 krukenberg carcinoma 30.8 NAPSA KRT7 HNF1B
7 lynch syndrome 30.8 TP53 PTEN PIK3CA MLH1 KRAS
8 appendix adenocarcinoma 30.7 KRT7 KRAS
9 ovarian clear cell adenocarcinoma 30.7 TP53 PIK3CA NAPSA HNF1B HIF1A ARID1A
10 serous cystadenocarcinoma 30.7 ZNF217 TP53 PTEN PPP2R1A PIK3CA KRAS
11 adenocarcinoma 30.6 TP53 PTEN PIK3CA NAPSA MLH1 KRT7
12 mucinous adenocarcinoma 30.6 TP53 MLH1 KRT7 KRAS
13 cystic teratoma 30.4 TP53 PTEN KRT7 KRAS
14 cervical adenocarcinoma 30.4 TP53 PTEN KRT7 KRAS
15 cystadenocarcinoma 30.4 ZNF217 TP53 PPP2R1A PIK3CA KRT7
16 papilloma 30.4 TP53 PTEN KRT7 KRAS
17 cowden syndrome 30.3 TP53 PTEN PIK3CA MLH1
18 teratoma 30.2 TP53 PTEN KRT7 KRAS GPC3
19 endometrial hyperplasia 30.2 TP53 PTEN MLH1 KRAS ARID1A
20 clear cell renal cell carcinoma 30.1 TP53 PTEN KRT7 HIF1A EZH2 ARID1A
21 endometrioid ovary carcinoma 30.1 TP53 PTEN PPP2R1A PIK3CA MLH1 KRAS
22 transitional cell carcinoma 30.0 TP53 PTEN MLH1 KRT7 EZH2 CD44
23 renal cell carcinoma, nonpapillary 29.9 TP53 PTEN PIK3CA NAPSA KRT7 HNF1B
24 endometrial cancer 29.9 TP53 PTEN PIK3CA MLH1 KRT7 KRAS
25 ovarian cancer 29.2 TP53 RSF1 PTEN PIK3CA MLH1 KRT7
26 endometriosis 10.9
27 ovarian epithelial cancer 10.8
28 anus basaloid carcinoma 10.4 PIK3CA KRT7
29 thyroid hurthle cell adenoma 10.4 PTEN PIK3CA
30 thrombophilia due to thrombin defect 10.4
31 endometriosis of ovary 10.4
32 pancreatic foamy gland adenocarcinoma 10.4 TP53 KRT7
33 ovarian carcinosarcoma 10.4 TP53 PIK3CA ARID1A
34 ovarian seromucinous carcinoma 10.4 TP53 KRT7
35 breast hemangioma 10.4 TP53 KRT7
36 bartholin's gland carcinoma 10.4 NAPSA KRT7
37 pancreatic signet ring cell adenocarcinoma 10.4 TP53 KRAS
38 malignant spiradenoma 10.4 TP53 PIK3CA KRT7
39 necrotizing sialometaplasia 10.4 TP53 KRT7
40 bladder clear cell adenocarcinoma 10.4 TP53 NAPSA KRT7
41 keratinizing squamous cell carcinoma 10.4 TP53 NAPSA KRT7
42 epithelial-myoepithelial carcinoma 10.4 TP53 PIK3CA KRT7
43 myoepithelial carcinoma 10.4 TP53 PIK3CA KRT7
44 keratosis, seborrheic 10.4 TP53 PIK3CA KRT7
45 rectosigmoid junction neoplasm 10.4 KRT7 KRAS
46 intratubular embryonal carcinoma 10.4 TP53 KRT7
47 sigmoid neoplasm 10.4 KRT7 KRAS
48 tonsil cancer 10.4 TP53 PIK3CA KRT7
49 renal pelvis transitional cell carcinoma 10.4 MLH1 KRT7
50 bone giant cell sarcoma 10.4 TP53 KRAS

Graphical network of the top 20 diseases related to Ovarian Clear Cell Carcinoma:



Diseases related to Ovarian Clear Cell Carcinoma

Symptoms & Phenotypes for Ovarian Clear Cell Carcinoma

GenomeRNAi Phenotypes related to Ovarian Clear Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 38)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-100 10.29 EZH2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.29 ZNF217
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-127 10.29 ZNF217
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-146 10.29 ARID1B
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-150 10.29 HNF1B
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-151 10.29 ZNF217
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-157 10.29 ARID1B HNF1B
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-159 10.29 ZNF217
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 10.29 ARID1B
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-167 10.29 HNF1B
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-168 10.29 HIF1A
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.29 ZNF217
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.29 HNF1B
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 10.29 HNF1B
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-185 10.29 HNF1B
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 10.29 ZNF217
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 10.29 HIF1A
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-214 10.29 EZH2 HNF1B
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.29 ZNF217
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-25 10.29 ZNF217
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.29 HNF1B
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-29 10.29 EZH2
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-35 10.29 EZH2
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-41 10.29 ARID1B
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-43 10.29 HNF1B
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-45 10.29 NAPSA
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.29 HNF1B
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-63 10.29 ZNF217
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.29 NAPSA
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-67 10.29 EZH2 ZNF217
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 10.29 HNF1B
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 10.29 EZH2
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 10.29 ARID1B EZH2 HNF1B ZNF217
34 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 10.29 HIF1A
35 Decreased shRNA abundance (Z-score < -2) GR00366-A-8 10.29 HNF1B
36 Decreased shRNA abundance (Z-score < -2) GR00366-A-80 10.29 HNF1B
37 Decreased shRNA abundance (Z-score < -2) GR00366-A-83 10.29 EZH2
38 Increased cell death in HCT116 cells GR00103-A-0 8.62 PIK3CA PPP2R1A

MGI Mouse Phenotypes related to Ovarian Clear Cell Carcinoma:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.42 ARID1A CCNE1 CD44 EZH2 FBXO5 GPC3
2 behavior/neurological MP:0005386 10.38 ANXA4 ARID1B CCNE1 CD44 EZH2 HIF1A
3 homeostasis/metabolism MP:0005376 10.35 ARID1A ARID1B CD44 EZH2 GPC3 HIF1A
4 cardiovascular system MP:0005385 10.34 ARID1A ARID1B CCNE1 CD44 EZH2 GPC3
5 growth/size/body region MP:0005378 10.34 ARID1A ARID1B CCNE1 CD44 EZH2 GPC3
6 mortality/aging MP:0010768 10.31 ARID1A ARID1B CCNE1 CD44 EZH2 FBXO5
7 embryo MP:0005380 10.3 ARID1A CCNE1 EZH2 FBXO5 GPC3 HIF1A
8 immune system MP:0005387 10.27 ARID1A ARID1B CCNE1 CD44 EZH2 GPC3
9 endocrine/exocrine gland MP:0005379 10.25 ARID1A CCNE1 CD44 EZH2 HIF1A HNF1B
10 integument MP:0010771 10.17 ARID1B CCNE1 CD44 EZH2 GPC3 HIF1A
11 digestive/alimentary MP:0005381 10.14 CCNE1 CD44 GPC3 HIF1A KRAS MLH1
12 muscle MP:0005369 10.07 ARID1A ARID1B CD44 EZH2 HIF1A HNF1B
13 neoplasm MP:0002006 10.06 ARID1A CCNE1 CD44 EZH2 HIF1A KRAS
14 normal MP:0002873 9.91 ARID1A CCNE1 CD44 EZH2 HIF1A KRAS
15 renal/urinary system MP:0005367 9.9 ANXA4 ARID1B CD44 EZH2 GPC3 HIF1A
16 respiratory system MP:0005388 9.56 CD44 EZH2 GPC3 HIF1A KRAS MLH1
17 skeleton MP:0005390 9.36 ARID1A CCNE1 CD44 EZH2 GPC3 HIF1A

Drugs & Therapeutics for Ovarian Clear Cell Carcinoma

Drugs for Ovarian Clear Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
2
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
3
Nintedanib Approved Phase 2 656247-17-5 56843413
4
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
5
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
6
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
7
Bevacizumab Approved, Investigational Phase 2 216974-75-3
8
Durvalumab Approved, Investigational Phase 2 1428935-60-7
9
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
10 Tubulin Modulators Phase 2
11 Antibiotics, Antitubercular Phase 2
12 topoisomerase I inhibitors Phase 2
13
Liposomal doxorubicin Phase 2 31703
14 Antimitotic Agents Phase 2
15 Albumin-Bound Paclitaxel Phase 2
16 Anti-Bacterial Agents Phase 2
17 Protein Kinase Inhibitors Phase 2
18 Angiogenesis Inhibitors Phase 2
19 Antineoplastic Agents, Immunological Phase 2
20 Antibodies Phase 1
21 Immunoglobulins Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Unknown status NCT02866370 Phase 2 Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
2 Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas Completed NCT01914510 Phase 2 ENMD-2076
3 Evaluation of the Efficacy of Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Completed NCT01824615 Phase 2 Sunitinib
4 A Phase II Evaluation of SU11248 (Sunitinib Malate) (NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma Completed NCT00979992 Phase 2 Sunitinib Malate
5 Sintilimab Plus Bevacizumab in Patients With Recurrent/Persistent Ovarian Clear Cell Carcinoma Recruiting NCT04735861 Phase 2 Sintilimab;Bevacizumab Biosimilar IBI305
6 A Multicentre Phase II Randomised Trial of Durvalumab (MEDI4736) Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas (MOCCA) Recruiting NCT03405454 Phase 2 durvalumab;standard chemotherapy
7 A Phase l Open-Label, Dose Escalation and Cohort Expansion Study, to Assess the Safety and Activity of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC) and Advanced or Metastatic Ovarian Clear Cell Carcinoma (OCCC) Terminated NCT02837991 Phase 1 CDX-014

Search NIH Clinical Center for Ovarian Clear Cell Carcinoma

Genetic Tests for Ovarian Clear Cell Carcinoma

Anatomical Context for Ovarian Clear Cell Carcinoma

MalaCards organs/tissues related to Ovarian Clear Cell Carcinoma:

40
Ovary, Kidney, Lymph Node, Breast, Brain, Cervix, Endothelial

Publications for Ovarian Clear Cell Carcinoma

Articles related to Ovarian Clear Cell Carcinoma:

(show top 50) (show all 650)
# Title Authors PMID Year
1
Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. 61
33509905 2021
2
Risk of second malignancy in patients with ovarian clear cell carcinoma. 61
33443021 2021
3
Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix. 61
33650653 2021
4
[Clinical Application of Gemcitabine plus Cisplatin plus Bevacizumab Combination Chemotherapy for Ovarian Clear Cell Carcinoma]. 61
33790161 2021
5
Pretreatment maximum standardized uptake value in 18F-fluorodeoxyglucose positron emission tomography-computed tomography as a prognostic factor for ovarian clear cell carcinoma and low-grade serous carcinoma. 61
33678332 2021
6
Evaluation of SWI/SNF Protein Expression by Immunohistochemistry in Ovarian Clear Cell Carcinoma. 61
32897960 2021
7
Prognostic and Theranostic Biomarkers in Ovarian Clear Cell Carcinoma. 61
33770057 2021
8
Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. 61
33768300 2021
9
Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression. 61
32897958 2021
10
NFAT Overexpression Correlates with CA72-4 and Poor Prognosis of Ovarian Clear-Cell Carcinoma Subtype. 61
33125687 2021
11
Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study. 61
33766002 2021
12
Diagnostic efficacy of ascites cell block for ovarian clear cell carcinoma. 61
33675673 2021
13
Molecular evidence for a clonal relationship between synchronous uterine endometrioid carcinoma and ovarian clear cell carcinoma: a new example of "precursor escape"? 61
33768299 2021
14
An immature inhibin-α-expressing subpopulation of ovarian clear cell carcinoma cells is related to an unfavorable prognosis. 61
33611864 2021
15
Up-regulation of HDAC6 Results in Poor Prognosis and Chemoresistance in Patients With Advanced Ovarian High-grade Serous Carcinoma. 61
33788761 2021
16
Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance. 61
33420363 2021
17
Extracellular miRNAs as Predictive Biomarkers for Glypican-3-Derived Peptide Vaccine Therapy Response in Ovarian Clear Cell Carcinoma. 61
33535558 2021
18
Clinical characteristics and prognostic factors of stage IC ovarian clear cell carcinoma: a Surveillance, Epidemiology, and End Results (SEER) analysis. 61
33543331 2021
19
Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma. 61
33541386 2021
20
Evaluation of Human Kidney Injury Molecule 1 (hKIM-1) Expression in Tumors From Various Organs by Messenger RNA In Situ Hybridization. 61
33608720 2021
21
Histopathology and ARID1A Expression in Endometriosis- Associated Ovarian Carcinoma (EAOC) Carcinogenesis Model with Endometrial Autoimplantation and DMBA Induction. 61
33639673 2021
22
Antioxidants and Therapeutic Targets in Ovarian Clear Cell Carcinoma. 61
33525614 2021
23
Suppression of ARID1A associated with decreased CD8 T cells improves cell survival of ovarian clear cell carcinoma. 61
33185044 2021
24
Residual Tumor Diameter Predicts Progression After Primary Debulking Surgery of Ovarian Clear Cell Carcinoma (OCCC): Clinicopathologic Study of Stage II-IV OCCC Patients from a Single Institution. 61
33692636 2021
25
Functional targeting of the TGF-βR1 kinase domain and downstream signaling: A role for the galloyl moiety of green tea-derived catechins in ES-2 ovarian clear cell carcinoma. 61
33017609 2021
26
Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma. 61
33758607 2021
27
Over-expression of RALYL suppresses the progression of ovarian clear cell carcinoma through inhibiting MAPK and CDH1 signaling pathways. 61
33437214 2021
28
cDNA expression library screening revealed novel functional genes involved in clear cell carcinogenesis of the ovary in vitro. 61
32157937 2021
29
Robot-assisted extraperitoneal para-aortic lymphadenectomy (RAePAL) performed with the bipolar cutting method. 61
33185047 2021
30
Hemoglobin-induced continuous activation of macrophages in endometriotic cysts: a potential mechanism of endometriosis development and carcinogenesis. 61
33392726 2021
31
p53 and ANXA4/NF‑κB p50 complexes regulate cell proliferation, apoptosis and tumor progression in ovarian clear cell carcinoma. 61
33125094 2020
32
Hypoxia-inducible Factor-1α Suppression in Ovarian Clear-cell Carcinoma Cells by Silibinin Administration. 61
33288572 2020
33
Tetraspanin 1 promotes endometriosis leading to ovarian clear cell carcinoma. 61
33331115 2020
34
Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report. 61
33292376 2020
35
Cysteine Deprivation Targets Ovarian Clear Cell Carcinoma Via Oxidative Stress and Iron-Sulfur Cluster Biogenesis Deficit. 61
32336105 2020
36
The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG. 61
33078599 2020
37
GSK-3β mediates the effects of HNF-1β overexpression in ovarian clear cell carcinoma. 61
33005248 2020
38
The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells. 61
32934721 2020
39
Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C. 61
33153119 2020
40
Phase I Study of P-cadherin-targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. 61
32816889 2020
41
Longitudinal ultrasound evaluation of clear-cell ovarian carcinoma. 61
31908070 2020
42
Transient commensal clonal interactions can drive tumor metastasis. 61
33199705 2020
43
High Expression of p21 as a Potential Therapeutic Target in Ovarian Clear-cell Carcinoma. 61
32988887 2020
44
Development and validation of Nomograms for predicting overall survival and Cancer-specific survival in patients with ovarian clear cell carcinoma. 61
33069259 2020
45
Effect of murine double-minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys. 61
32713096 2020
46
Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma. 61
32929152 2020
47
Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma. 61
33116254 2020
48
Natural killer cell impairment in ovarian clear cell carcinoma. 61
32794325 2020
49
Adjuvant Treatment of Early Ovarian Clear Cell Carcinoma: A Population-Based Study of Whole Abdominal Versus Pelvic Nodal Radiotherapy. 61
32971514 2020
50
Multiregion whole-genome sequencing depicts intratumour heterogeneity and punctuated evolution in ovarian clear cell carcinoma. 61
31862729 2020

Variations for Ovarian Clear Cell Carcinoma

Copy number variations for Ovarian Clear Cell Carcinoma from CNVD:

7 (show top 50) (show all 427)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13831 1 1 88452 Loss Ovarian clear cell carcinoma
2 14094 1 103933871 104104913 Loss Ovarian clear cell carcinoma
3 14228 1 105814888 105835737 Loss Ovarian clear cell carcinoma
4 14767 1 110029012 110047636 Gain Ovarian clear cell carcinoma
5 14768 1 110029027 110046508 Loss Ovarian clear cell carcinoma
6 15067 1 112489835 112507466 Gain Ovarian clear cell carcinoma
7 15068 1 112491838 112507466 Loss Ovarian clear cell carcinoma
8 18079 1 143856437 146851948 Gain Ovarian clear cell carcinoma
9 18686 1 147137550 147788457 Gain Ovarian clear cell carcinoma
10 18898 1 147703455 147884062 Loss Ovarian clear cell carcinoma
11 18938 1 147964875 159663147 Gain Ovarian clear cell carcinoma
12 18939 1 147964875 159663147 Gain Ovarian clear cell carcinoma
13 19585 1 150821801 150857105 Loss Ovarian clear cell carcinoma
14 19705 1 151026303 151040528 Loss Ovarian clear cell carcinoma
15 21673 1 16022491 16026775 Gain Ovarian clear cell carcinoma
16 21674 1 16024203 16038247 Loss Ovarian clear cell carcinoma
17 22558 1 167482724 167509012 Loss Ovarian clear cell carcinoma
18 22559 1 167482724 167521488 Gain Ovarian clear cell carcinoma
19 22780 1 16889448 16921459 Gain Ovarian clear cell carcinoma
20 24231 1 177344731 177346824 Loss Ovarian clear cell carcinoma
21 24465 1 180956979 181720785 Gain Ovarian clear cell carcinoma
22 25838 1 194981485 195068682 Gain Ovarian clear cell carcinoma
23 25839 1 194981485 195083340 Loss Ovarian clear cell carcinoma
24 26133 1 197378133 197380848 Loss Ovarian clear cell carcinoma
25 26790 1 202780704 202781223 Loss Ovarian clear cell carcinoma
26 27522 1 209500000 222100000 Amplification CENPF Ovarian clear cell carcinoma
27 28170 1 219471 557615 Gain Ovarian clear cell carcinoma
28 28576 1 223563323 234670833 Gain Ovarian clear cell carcinoma
29 29195 1 228800000 234600000 Amplification TARBP1 Ovarian clear cell carcinoma
30 29315 1 230223390 230231832 Loss Ovarian clear cell carcinoma
31 29845 1 236917532 236921700 Loss Ovarian clear cell carcinoma
32 29954 1 238458352 238460749 Loss Ovarian clear cell carcinoma
33 30919 1 246707804 246877268 Gain Ovarian clear cell carcinoma
34 30947 1 246804059 246863823 Loss Ovarian clear cell carcinoma
35 31115 1 25455917 25517758 Gain Ovarian clear cell carcinoma
36 31116 1 25455917 25534075 Loss Ovarian clear cell carcinoma
37 32697 1 38901189 38907774 Gain Ovarian clear cell carcinoma
38 36176 1 72522942 72600553 Loss Ovarian clear cell carcinoma
39 36192 1 72535947 72584491 Gain Ovarian clear cell carcinoma
40 37128 1 85775755 85782373 Loss Ovarian clear cell carcinoma
41 37531 1 92007142 92023072 Loss Ovarian clear cell carcinoma
42 39168 10 11150202 11151804 Loss Ovarian clear cell carcinoma
43 41309 10 15959139 15974926 Loss Ovarian clear cell carcinoma
44 41503 10 19683194 19835050 Loss Ovarian clear cell carcinoma
45 41826 10 24415258 24418944 Gain Ovarian clear cell carcinoma
46 41827 10 24415258 24420691 Loss Ovarian clear cell carcinoma
47 42276 10 31286505 31291815 Loss Ovarian clear cell carcinoma
48 42716 10 3813637 3819468 Gain Ovarian clear cell carcinoma
49 42973 10 4276898 4287271 Gain Ovarian clear cell carcinoma
50 43007 10 42910287 42910797 Gain Ovarian clear cell carcinoma

Expression for Ovarian Clear Cell Carcinoma

Search GEO for disease gene expression data for Ovarian Clear Cell Carcinoma.

Pathways for Ovarian Clear Cell Carcinoma

Pathways related to Ovarian Clear Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.92 TP53 PTEN PPP2R1A PIK3CA KRAS CCNE1
2
Show member pathways
12.8 TP53 PTEN PIK3CA MLH1 KRAS CCNE1
3
Show member pathways
12.68 TP53 PTEN PPP2R1A PIK3CA KRAS
4 12.64 TP53 PTEN PIK3CA MLH1 KRAS HIF1A
5
Show member pathways
12.63 TP53 PTEN PIK3CA KRAS CCNE1
6
Show member pathways
12.54 TP53 PTEN PIK3CA KRAS HIF1A
7
Show member pathways
12.43 TP53 PTEN PIK3CA KRAS GPC3
8
Show member pathways
12.35 PIK3CA KRAS GPC3 CD44
10 12.25 TP53 PIK3CA KRAS CCNE1
11
Show member pathways
12.25 PPP2R1A PIK3CA KRAS FBXO5 CCNE1
12 12.22 TP53 PTEN PIK3CA KRAS CCNE1
13
Show member pathways
12.2 TP53 PTEN HIF1A CCNE1
14 12.19 TP53 PTEN PIK3CA KRAS EZH2 CD44
15 12.05 TP53 PIK3CA KRAS HIF1A GPC3 CD44
16 12.02 PTEN PIK3CA KRAS HIF1A
17 12 TP53 PTEN PIK3CA KRAS CCNE1
18 11.94 TP53 PIK3CA KRAS HIF1A
19 11.9 TP53 PTEN PIK3CA KRAS
20
Show member pathways
11.89 TP53 PTEN PIK3CA MLH1 KRAS CCNE1
21 11.87 TP53 PTEN KRAS CCNE1
22 11.8 TP53 PTEN PPP2R1A PIK3CA KRAS
23 11.78 TP53 PTEN PIK3CA CCNE1
24 11.69 TP53 PIK3CA MLH1
25 11.66 TP53 KRAS HIF1A
26
Show member pathways
11.6 HIF1A CCNE1 ARID1B ARID1A
27 11.55 TP53 PTEN PIK3CA ARID1A
28 11.53 PTEN PIK3CA HIF1A
29 11.53 TP53 PTEN PIK3CA
30 11.49 TP53 HIF1A CD44
31 11.2 PTEN PIK3CA KRAS
32 11.2 TP53 PTEN PIK3CA KRAS HIF1A
33 10.74 TP53 HIF1A
34 10.3 TP53 CCNE1

GO Terms for Ovarian Clear Cell Carcinoma

Cellular components related to Ovarian Clear Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.03 ZNF217 TP53 RSF1 PTEN PPP2R1A MLH1
2 nucleoplasm GO:0005654 9.73 ZNF217 TP53 RSF1 PTEN MLH1 HNF1B
3 brahma complex GO:0035060 8.62 ARID1B ARID1A

Biological processes related to Ovarian Clear Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.8 TP53 PTEN HIF1A CD44 ANXA4
2 cell migration GO:0016477 9.67 PTEN PIK3CA GPC3 CD44
3 positive regulation of transcription, DNA-templated GO:0045893 9.63 TP53 RSF1 HNF1B HIF1A ARID1B ARID1A
4 liver development GO:0001889 9.5 PIK3CA KRAS HNF1B
5 chromatin-mediated maintenance of transcription GO:0048096 9.26 ARID1B ARID1A
6 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 8.96 TP53 HIF1A
7 regulation of thymocyte apoptotic process GO:0070243 8.62 TP53 HIF1A

Molecular functions related to Ovarian Clear Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.62 ZNF217 TP53 RSF1 PTEN PPP2R1A PIK3CA
2 protein kinase binding GO:0019901 9.55 TP53 PTEN HIF1A FBXO5 CCNE1
3 anaphase-promoting complex binding GO:0010997 8.96 PTEN FBXO5

Sources for Ovarian Clear Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....